Teva gets taste of its own antidepressant

At least seven of the 16 firms with approvals for generic sertraline hydrochloride decide to launch their versions of Pfizer's antidepressant Zoloft after Teva's 180-day exclusivity expired Feb. 6. In January, Teva filed patent infringement lawsuits against multiple generic manufacturers, claiming the generics violate patents which relate to methods for manufacturing. According to IMS data, the generic substitution rate for Zoloft was 89 percent as of Dec. 15, with Teva controlling 45.4 percent of the generic share. The remaining portion went to Greenstone, Pfizer's authorized generics business...